The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A multicenter, randomized, phase Ib/II trial of the oral c-Met inhibitor MSC2156119J as monotherapy versus sorafenib in Asian patients with MET-positive (MET+) advanced hepatocellular carcinoma (HCC) and Child-Pugh Class A liver function.
Shukui Qin
No relevant relationships to disclose
Ann-Lii Cheng
Consultant or Advisory Role - Bayer; Exelixis; Merck
Honoraria - Bayer; Exelixis; Merck
Research Funding - Chugai Pharma; Sanofi
Ho Yeong Lim
No relevant relationships to disclose
Lianzhe Xu
Employment or Leadership Position - Merck Serono
Friedhelm Bladt
Employment or Leadership Position - Merck KGaA
Andreas Johne
Employment or Leadership Position - Merck KGaA
Cindy Li
Employment or Leadership Position - Merck Serono
Hongxia Zheng
Employment or Leadership Position - EMD Serono
Giorgio Massimini
Employment or Leadership Position - Merck KGaA